Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 25;13(3):220.
doi: 10.3390/cells13030220.

Beyond Allergies-Updates on The Role of Mas-Related G-Protein-Coupled Receptor X2 in Chronic Urticaria and Atopic Dermatitis

Liron Lerner  1   2 , Magda Babina  1   2 , Torsten Zuberbier  1   2 , Katarina Stevanovic  1   2
Affiliations

Beyond Allergies-Updates on The Role of Mas-Related G-Protein-Coupled Receptor X2 in Chronic Urticaria and Atopic Dermatitis

Liron Lerner et al. Cells. .

Abstract

Mast cells (MCs) are an important part of the immune system, responding both to pathogens and toxins, but they also play an important role in allergic diseases, where recent data show that non-IgE-mediated activation is also of relevance, especially in chronic urticaria (CU) and atopic dermatitis (AD). Skin MCs express Mas-related G-protein-coupled receptor X2 (MRGPRX2), a key protein in non-IgE-dependent MC degranulation, and its overactivity is one of the triggering factors for the above-mentioned diseases, making MRGPRX2 a potential therapeutic target. Reviewing the latest literature revealed our need to focus on the discovery of MRGPRX2 activators as well as the ongoing vast research towards finding specific MRGPRX2 inhibitors for potential therapeutic approaches. Most of these studies are in their preliminary stages, with one drug currently being investigated in a clinical trial. Future studies and improved model systems are needed to verify whether any of these inhibitors may have the potential to be the next therapeutic treatment for CU, AD, and other pseudo-allergic reactions.

Keywords: MRGPRX2; atopic dermatitis; skin mast cells; urticaria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PubMed search strategy and selection of articles for inclusion in this review.
Figure 2
Figure 2
An illustration of the theoretical modes of action of the MRGPRX2 signaling pathway inhibitors. The inhibition symbol represents generalized inhibition including reduction in phosphorylation, reduction in expression, or direct inhibition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Finlay A.Y. The burden of skin disease: Quality of life, economic aspects and social issues. Clin. Med. 2009;9:592–594. doi: 10.7861/clinmedicine.9-6-592. - DOI - PMC - PubMed
    1. Chu S., Mehrmal S., Uppal P., Giesey R.L., Delost M.E., Delost G.R. Burden of skin disease and associated socioeconomic status in Europe: An ecologic study from the Global Burden of Disease Study 2017. JAAD Int. 2020;1:95–103. doi: 10.1016/j.jdin.2020.07.001. - DOI - PMC - PubMed
    1. Zuberbier T., Lotvall J., Simoens S., Subramanian S.V., Church M.K. Economic burden of inadequate management of allergic diseases in the European Union: A GA(2) LEN review. Allergy. 2014;69:1275–1279. doi: 10.1111/all.12470. - DOI - PubMed
    1. Langan S.M., Mulick A.R., Rutter C.E., Silverwood R.J., Asher I., García-Marcos L., Ellwood E., Bissell K., Chiang C.-Y., Sony A.E., et al. Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study. Clin. Exp. Allergy. 2023;53:337–352. doi: 10.1111/cea.14276. - DOI
    1. Goncalo M., Gimenez-Arnau A., Al-Ahmad M., Ben-Shoshan M., Bernstein J.A., Ensina L.F., Fomina D., Galvan C.A., Godse K., Grattan C., et al. The global burden of chronic urticaria for the patient and society. Br. J. Dermatol. 2021;184:226–236. doi: 10.1111/bjd.19561. - DOI - PubMed

MeSH terms

LinkOut - more resources